Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares

Core Viewpoint - Centessa Pharmaceuticals plc has initiated an underwritten public offering of American Depositary Shares (ADSs), with all shares being offered by the company, and plans to grant underwriters a 30-day option to purchase an additional 15% of the ADSs offered [1][2]. Company Overview - Centessa Pharmaceuticals is a clinical-stage pharmaceutical company focused on discovering, developing, and delivering transformative medicines for patients, particularly through its orexin receptor 2 (OX2R) agonist program aimed at treating excessive daytime sleepiness, cognitive deficits, and other neurological disorders [5]. Offering Details - The ADSs are being offered under a registration statement on Form S-3 filed with the SEC on September 11, 2024, which became effective upon filing [3]. - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and will be accessible on the SEC's website [3]. Underwriters - Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities are serving as joint book-running managers for the offering, while Oppenheimer & Co., Truist Securities, and LifeSci Capital are acting as co-lead managers [2]. Contact Information - For inquiries, the company has provided contact details for Kristen K. Sheppard, SVP of Investor Relations [7].